Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.

ABSTRACT:

SUBMITTER: Chen GL 

PROVIDER: S-EPMC8786321 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature